← FDA DRUG APPROVALS

FDA NDA · NDA050633

CEFPIRAMIDE SODIUM

Sponsor: WYETH AYERST

APPLICATION
NDA050633
TYPE
NDA
ORIGINAL APPROVAL
1989-01-31
LATEST ACTION
1991-08-21
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

CEFPIRAMIDE SODIUMDiscontinued
CEFPIRAMIDE SODIUM EQ 1GM BASE/VIAL · INJECTABLE · INJECTION
CEFPIRAMIDE SODIUMDiscontinued
CEFPIRAMIDE SODIUM EQ 10GM BASE/VIAL · INJECTABLE · INJECTION
CEFPIRAMIDE SODIUMDiscontinued
CEFPIRAMIDE SODIUM EQ 2GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

1991-08-21Manufacturing (CMC) · Supplement 4 · standardAP
1989-05-10Manufacturing (CMC) · Supplement 2 · standardAP
1989-01-31Type 1 - New Molecular Entity · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →